Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma

被引:77
|
作者
Wang, Chenyang [1 ]
Kaprealian, Tania B. [1 ]
Suh, John H. [2 ]
Kubicky, Charlotte D. [3 ]
Ciporen, Jeremy N. [4 ]
Chen, Yiyi [5 ]
Jaboin, Jerry J. [3 ]
机构
[1] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90024 USA
[2] Cleveland Clin, Dept Radiat Oncol, Cleveland, OH 44106 USA
[3] Oregon Hlth & Sci Univ, Dept Radiat Med, 3181 SW Sam Jackson Pk Rd,L337, Portland, OR 97239 USA
[4] Oregon Hlth & Sci Univ, Dept Neurosurg, Ctr Hlth & Healing, Portland, OR 97201 USA
[5] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA
关键词
adjuvant radiotherapy; NCDB; overall survival; propensity score; WHO grade II meningioma; ATYPICAL CRANIAL MENINGIOMAS; CENTRAL-NERVOUS-SYSTEM; GROSS-TOTAL RESECTION; POSTOPERATIVE RADIOTHERAPY; INTRACRANIAL MENINGIOMAS; MALIGNANT MENINGIOMAS; UNITED-STATES; PRIMARY BRAIN; FOLLOW-UP; RECURRENCE;
D O I
10.1093/neuonc/nox007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Adjuvant radiotherapy (RT) after surgical resection of World Health Organization (WHO) grade II meningioma, also known as atypical meningioma (AM), is a topic of controversy. The purpose of this study is to compare overall survival (OS) with or without adjuvant RT after subtotal resection (STR) or gross total resection (GTR) in AM patients diagnosed according to the 2007 WHO classification. Methods. The National Cancer Database was used to identify 2515 patients who were diagnosed with AM between 2009 and 2012 and underwent STR or GTR with or without adjuvant RT. Propensity score matching was first applied to balance covariates including age, year of diagnosis, sex, race, histology, and tumor size in STR or GTR cohorts stratified by adjuvant RT status. Multivariate regression according to the Cox proportional hazards model and Kaplan-Meier survival plots with log-rank test were then used to evaluate OS difference associated with adjuvant RT. Results. GTR is associated with improved OS compared with STR. In the subgroup analysis, adjuvant RT in patients who underwent STR demonstrated significant association with improved OS compared with no adjuvant RT (adjusted hazard ratio [AHR] 0.590, P =.045); however, adjuvant RT is not associated with improved OS in patients who underwent GTR (AHR 1.093, P =.737). Conclusions. Despite the lack of consensus on whether adjuvant RT reduces recurrence after surgical resection of AM, our study observed significantly improved OS with adjuvant RT compared with no adjuvant RT after STR.
引用
收藏
页码:1263 / 1270
页数:8
相关论文
共 50 条
  • [31] Association between Facility Volume and Overall Survival for Patients with Grade II Meningioma after Gross Total Resection
    Anakwenze, Chidinma
    McGovern, Susan
    Taku, Nicolette
    Liao, Kaiping
    Boyce-Fappiano, David
    Kamiya-Matsuoka, Carlos
    Ghia, Amol
    Chung, Caroline
    Li, Jing
    Yeboa, Debra Nana
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (02): : E7 - E7
  • [32] Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma
    Lin, Huapeng
    Li, Xiaocheng
    Liu, Ye
    Hu, Yingchun
    ANZ JOURNAL OF SURGERY, 2018, 88 (10) : E718 - E724
  • [33] The effect of the revised WHO classification on the incidence of grade II meningioma
    Bulleid, Lindsey S.
    James, Zoe
    Lammie, Alistair
    Hayhurst, Caroline
    Leach, Paul A.
    BRITISH JOURNAL OF NEUROSURGERY, 2020, 34 (05) : 584 - 586
  • [34] MENINGIOMA WHO GRADE II-III: TEMOZOLOMIDE WITH AND WITHOUT RADIATION IN THE MANAGEMENT OF WHO GRADE II AND III MENINGIOMAS
    Clark, Sarah
    Carlson, Julie A.
    Gaspar, Laurie E.
    Ney, Doug E.
    Chen, Changhu
    Kavanagh, Brian
    Damek, Denise M.
    NEURO-ONCOLOGY, 2012, 14 : 59 - 59
  • [35] Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma
    Dorota Lubgan
    Sandra Rutzner
    Ulrike Lambrecht
    Karl Rössler
    Michael Buchfelder
    Ilker Eyüpoglu
    Rainer Fietkau
    Sabine Semrau
    Journal of Neuro-Oncology, 2017, 134 : 407 - 416
  • [36] Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma
    Jenkinson, Michael D.
    Weber, Damien C.
    Haylock, Brian J.
    Sherratt, Frances C.
    Young, Bridget
    Weller, Michael
    Bulbeck, Helen
    Culeddu, Giovanna
    Hughes, Dyfrig A.
    Brain, Alice
    Das, Kumar
    Preusser, Matthias
    Francis, Priya
    Gamble, Carrol
    JOURNAL OF NEUROSURGERY, 2018, 129 (04) : 1104 - 1105
  • [37] Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma
    Lubgan, Dorota
    Rutzner, Sandra
    Lambrecht, Ulrike
    Roessler, Karl
    Buchfelder, Michael
    Eyuepoglu, Ilker
    Fietkau, Rainer
    Semrau, Sabine
    JOURNAL OF NEURO-ONCOLOGY, 2017, 134 (02) : 407 - 416
  • [38] IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas
    Adriana Olar
    Khalida M. Wani
    Kristin D. Alfaro-Munoz
    Lindsey E. Heathcock
    Hinke F. van Thuijl
    Mark R. Gilbert
    Terri S. Armstrong
    Erik P. Sulman
    Daniel P. Cahill
    Elizabeth Vera-Bolanos
    Ying Yuan
    Jaap C. Reijneveld
    Bauke Ylstra
    Pieter Wesseling
    Kenneth D. Aldape
    Acta Neuropathologica, 2015, 129 : 585 - 596
  • [39] Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma
    Hemmati, Saman Moritz
    Ghadjar, Pirus
    Gruen, Arne
    Badakhshi, Harun
    Zschaeck, Sebastian
    Senger, Carolin
    Acker, Gueliz
    Misch, Martin
    Budach, Volker
    Kaul, David
    RADIATION ONCOLOGY, 2019, 14 (01)
  • [40] Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma
    Saman Moritz Hemmati
    Pirus Ghadjar
    Arne Grün
    Harun Badakhshi
    Sebastian Zschaeck
    Carolin Senger
    Güliz Acker
    Martin Misch
    Volker Budach
    David Kaul
    Radiation Oncology, 14